Emergent Stock Valuation

EBS
 Stock
  

USD 20.69  0.73  3.41%   

How much is Emergent Biosolutions worth today? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Emergent Biosolutions, is its stock price multiplied by the total number of shares outstanding, calculating Emergent Biosolutions' enterprise value requires a different approach. It uses Emergent Biosolutions' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Emergent Biosolutions shows a prevailing Real Value of $30.68 per share. The current price of the firm is $20.69. At this time, the firm appears to be undervalued. Our model computes the value of Emergent Biosolutions from reviewing the firm fundamentals such as Shares Outstanding of 53.8 M, current valuation of 2.17 B, and Profit Margin of 8.96 % as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we advise buying undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
  
Emergent Biosolutions Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Emergent Biosolutions's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Undervalued
Today 20.69
Please note that Emergent Biosolutions' price fluctuation is not too volatile at this time. Calculation of the real value of Emergent Biosolutions is based on 3 months time horizon. Increasing Emergent Biosolutions' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Emergent Biosolutions is useful when determining the fair value of the Emergent stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Emergent Biosolutions. Since Emergent Biosolutions is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Emergent Stock. However, Emergent Biosolutions' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
30.68
Real Value
34.17
Upside
Estimating the potential upside or downside of Emergent Biosolutions helps investors to forecast how Emergent stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Emergent Biosolutions more accurately as focusing exclusively on Emergent Biosolutions' fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
19.4922.1324.76
Details
Hype
Prediction
LowEstimated ValueHigh
17.2320.7224.21
Details
Naive
Forecast
LowNext ValueHigh
16.7220.2123.71
Details
6 Analysts
Consensus
LowTarget PriceHigh
50.0062.5075.00
Details

Emergent Biosolutions Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Emergent Biosolutions's current stock value. Our valuation model uses many indicators to compare Emergent Biosolutions value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Emergent Biosolutions competition to find correlations between indicators driving Emergent Biosolutions's intrinsic value. More Info.
Emergent Biosolutions is one of the top stocks in price to sales category among related companies. It is one of the top stocks in price to earning category among related companies reporting about  4.56  of Price to Earning per Price to Sales. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Emergent Biosolutions by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Emergent Biosolutions' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Emergent Biosolutions' earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Emergent Biosolutions' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Emergent Biosolutions and how it compares across the competition.

About Emergent Biosolutions Valuation

The stock valuation mechanism determines the current worth of Emergent Biosolutions on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Emergent Biosolutions. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Emergent Biosolutions based exclusively on its fundamental and basic technical indicators. By analyzing Emergent Biosolutions's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Emergent Biosolutions's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Emergent Biosolutions. We calculate exposure to Emergent Biosolutions's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Emergent Biosolutions's related companies.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Emergent Biosolutions operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 2416 people.

Emergent Biosolutions Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Emergent Biosolutions does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio2.48
Revenue Growth-10.30%
Enterprise Value To Ebitda5.06
Enterprise Value To Revenue1.23
Continue to Investing Opportunities. Note that the Emergent Biosolutions information on this page should be used as a complementary analysis to other Emergent Biosolutions' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for Emergent Stock analysis

When running Emergent Biosolutions price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Is Emergent Biosolutions' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emergent Biosolutions. If investors know Emergent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emergent Biosolutions listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Emergent Biosolutions is measured differently than its book value, which is the value of Emergent that is recorded on the company's balance sheet. Investors also form their own opinion of Emergent Biosolutions' value that differs from its market value or its book value, called intrinsic value, which is Emergent Biosolutions' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emergent Biosolutions' market value can be influenced by many factors that don't directly affect Emergent Biosolutions' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emergent Biosolutions' value and its price as these two are different measures arrived at by different means. Investors typically determine Emergent Biosolutions value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emergent Biosolutions' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.